Novo Nordisk (NOVO) Q3 2024 London conference call earnings summary

Executive summary

• Sales grew 24% at constant exchange rates (CER) in the first nine months of 2024, driven by strong demand for GLP-1 diabetes and obesity treatments, with operating profit up 22% (CER) and net profit up 18%.

• GLP-1 portfolio for diabetes and obesity was the main growth driver, with global GLP-1 market share rising to 65%.

• Obesity care sales surged 44% (CER), rare disease sales increased 3% (CER), and over 43 million patients now use products.

• Free cash flow reached DKK 71.8 billion, with DKK 56.9 billion returned to shareholders.

• Strategic focus remains on diabetes, obesity, rare diseases, and expansion into cardiovascular, liver, kidney, and Alzheimer's disease areas.

Financial highlights

• Sales: DKK 204.7 billion, up 24% (CER) year-over-year; operating profit: DKK 91.6 billion, up 22% (CER); net profit: DKK 72.8 billion, up 18%.

• Gross margin improved to 84.6%, EBITDA up 28% to DKK 105.5 billion.

• Diluted EPS increased 19% to DKK 16.29.

• Free cash flow: DKK 71.8 billion; DKK 57 billion returned to shareholders year-to-date.

• R&D costs: DKK 34.3 billion, up 56% year-over-year, representing 16.7% of sales.

Outlook and guidance

• 2024 sales growth expected at 23–27% (CER), with operating profit growth at 21–27% (CER).

• Effective tax rate guidance remains at 20–21%; free cash flow expected between DKK 57–65 billion.

• Guidance for 2025 to be provided in February; current growth driven by volume, not price.

• Currency headwinds expected to reduce operating profit by ~2 percentage points.

• Guidance reflects continued strong GLP-1 demand, ongoing supply constraints, and pricing pressure.